EMA concerned about MAA delays, working on solutions

The European Medicines Agency (EMA) and the European Medicines Regulatory Network are concerned that marketing authorization applications (MAA) are not being handled efficiently, leading to significant delays in reviewing and ultimately bringing products to market. The agency recently held a stakeholder meeting on the topic and is engaged in several initiatives to find potential solutions.